PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 3, 2009, Pages 719-729

  Soderquist, Ryan G ^a   Milligan, Erin D ^b   Sloane, Evan M ^b   Harrison, Jacqueline A ^b   Douvas, Klarika K ^a   Potter, Joseph M ^b   Hughes, Travis S ^b   Chavez, Raymond A ^c   Johnson, Kirk ^c   Watkins, Linda R ^b   Mahoney, Melissa J ^a  

^a University of Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Avigen Inc   (United States)

Author keywords

Biological activity; Brain derived neurotrophic factor; Confocal microscopy; Intrathecal drug delivery; PEGylation

Indexed keywords

BIOLOGICAL ACTIVITIES; BIOLOGICAL ACTIVITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTORS; CEREBRO SPINAL FLUIDS; ENHANCED PENETRATION; HIGHER ORDER; IN-VITRO; IN-VIVO; INTRATHECAL; INTRATHECAL DRUG DELIVERY; PEGYLATION; REACTION CONDITIONS; SPINAL CORDS; SUBSTANTIAL REDUCTION; THERAPEUTIC PROTEIN;

BIOACTIVITY; BODY FLUIDS; CONFOCAL MICROSCOPY; DOSIMETRY; DRUG DELIVERY; MIXTURES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES;

BRAIN;

BRAIN DERIVED NEUROTROPHIC FACTOR; POLYETHYLENE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROTEIN STABILITY; RAT;

ALDEHYDES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DRUG DELIVERY SYSTEMS; ESTERS; INJECTIONS, SPINAL; MALE; MASS SPECTROMETRY; MICROSCOPY, CONFOCAL; NEURONS; PC12 CELLS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 70350346602     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32254     Document Type: Article

References (51)

1. Stroh M, Zipfel WR, Williams RM, Ma SC, Webb WW, Saltzman WM. Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion. Nat Mater 2004;3:489-494.
2. Ankeny DP, McTigue DM, Guan Z, Yan Q, Kinstler O, Stokes BT, Jakeman LB. Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury. Exp Neurol 2001;170:85-100. (Pubitemid 32641776)
3. Kishino A, Katayama N, Ishige Y, Yamamoto Y, Ogo H, Tatsuno T, Mine T, Noguchi H, Nakayama C. Analysis of effects and pharmacokinetics of subcutaneously administered BDNF. Neuroreport 2001;12:1067-1072. (Pubitemid 32281476)
4. Encinas M, Iglesias M, Llecha N, Comella JX. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SHSY5Y. J Neurochem 1999;73:1409-1421. (Pubitemid 29440140)
5. Miki K, Fukuoka T, Tokunaga A, Kondo E, Dai Y, Noguchi K. Differential effect of brain-derived neurotrophic factor on high-threshold mechanosensitivity in a rat neuropathic pain model. Neurosci Lett 2000;278:85-88. (Pubitemid 30009903)
6. Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated overexpression of BDNF in the rat spinal cord. Gene Ther 2002;9:1387-1395. (Pubitemid 35244164)
7. Bergman I, Burckart GJ, Pohl CR, Venkataramanan R, Barmada MA, Griffin JA, Cheung NKV. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. J Pharmacol Exp Ther 1998; 284:111-115. (Pubitemid 28109536)
8. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 2002;54:587-606. (Pubitemid 34615549)
9. Dang W, Colvin MO, Brem H, Saltzman WM. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res 1994;54:1729-1735. (Pubitemid 24116177)
10. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D. PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques. Int J Hematol 1998;68:1-18. (Pubitemid 28368166)
11. Belcheva N, Woodrow-Mumford K, Mahoney MJ, Saltzman WM. Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate. Bioconjug Chem 1999;10:932-937.
12. Lee H, Jang IH, Ryu SH, Park TG. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res 2003;20:818-825. (Pubitemid 36515317)
13. Krinner EM, Hepp J, Hoffmann P, Bruckmaier S, Petersen L, Petsch S, Parr L, Schuster I, Mangold S, Lorenczewski G, Lutterbuse P, Buziol S, Hochheim I, Volkland J, Molhoj M, Sriskandarajah M, Strasser M, Itin C, Wolf A, Basu A, Yang K, Filpula D, Sorensen P, Kufer P, Baeuerle P, Raum T. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng Des Sel 2006;19:461-470. (Pubitemid 44408906)
14. Yun Q, Xing WC, Mal GG, Su ZG. Preparation and characterization of mono-PEGylated consensus interferon by a novel polyethylene glycol derivative. J Chem Technol Biotechnol 2006;81:776-781. (Pubitemid 43670630)
15. Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-alpha 2b: A branched 40K polyethylene glycol derivative. Pharm Res 2005;22:1374-1386. (Pubitemid 41176042)
16. Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 1996;13:996-1002.
17. Tsutsami Y, Tsunoda S-I, Kamada H, Kihira T, Kaneda Y, Ohsugi Y, Mayumi T. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 1997;77:168-173. (Pubitemid 27064988)
18. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998;15:576-582. (Pubitemid 28214951)
19. Katre NV, Knauf MJ, Laird WL. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sacroma model. Proc Natl Acad Sci USA 1987;84:1487-1491.
20. Hudecz F, Clegg JA, Kajtar J, Embleton MJ, Pimm MV, Szekerke M, Baldwin RW. Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate-branched polypeptide conjugates. Bioconjug Chem 1993;4:25-33.
21. Sakane T, Pardridge WM. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res 1997;14:1085-1091. (Pubitemid 27371411)
22. Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, Chuntharapai A, Kim KJ, Tumas DB, Lee WP, Gribling P, Snedecor B, Chen H, Hsei V, Schoenhoff M, Hale V, Deveney J, Koumenis I, Shahrokh Z, McKay P, Galan W, Wagner B, Narindray D, Hebert C, Zapata G. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 2001;16:106-119. (Pubitemid 34081705)
23. Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000;198:83-95.
24. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima F, Chang S, Chu H, Mukku V, CanovaDavis E, Somer T, Cronin M, Winkler M, Wells JA. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271:21969-21977. (Pubitemid 26303822)
25. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1:352-356.
26. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54:459-476.
27. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002;54:477-485.
28. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconjug Chem 2005;16:200-207.
29. Na DH, Lee KC, DeLuca PP. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm Res 2005;22:743-749.
30. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'Connor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005;21:2136-2148. (Pubitemid 40695238)
31. Milligan ED, O'Connor KA, Nguyen K, Armstrong CB, Twining C, Gaykema RPA, Holguin A, Martin D, Maier SF, Watkins LR. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 2001;21:2808-2819. (Pubitemid 32298222)
32. Mannes A, Caudle R, O'Connell B, Iadarola M. Adenoviral gene transfer to spinal cord neurons: Intrathecal vs. intraparenchymal administration. Brain Res 1998;793:1-6. (Pubitemid 28294066)
33. Milligan ED, Sloane EM, Langer SJ, Cruz PE, Chacur M, Spataro L, Wieseler-Frank J, Hammack SE, Maier SF, Flotte TR, Forsayeth JR, Leinwand LA, Chavez RA, Watkins LR. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 2005;1:1-9. (Pubitemid 44848613)
34. Greene LA, Aletta JM, Rukenstein A, Green SH. PC12 pheochromocytoma cells: Culture, nerve growth factor treatment, and experimental exploitation. Methods Enzymol 1987;147: 207-216. (Pubitemid 18013020)
35. Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23(8, Part 2): 3S-8S. (Pubitemid 36904012)
36. Gaertner H, Offord R. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug Chem 1996;7:38-44. (Pubitemid 2617060)
37. Lee H, Park TG. Preparation and characterization of mono-PEGylated epidermal growth factor: Evaluation of in vitro biologic activity. Pharm Res 2002;19:845-851. (Pubitemid 34686745)
38. Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharm 2005;68:1439-1454. (Pubitemid 41540000)
39. Robinson RC, Radziejewski C, Stuart DI, Jones EY. Structure of the brain-derived neurotrophic factor neurotrophin 3 heterodimer. Biochemistry 1995;34:4139-4146.
40. Cindric M, Cepo T, Galic N, Bukvic-Krajacic M, Tomczyk N, Vissers JPC, Bindila L, Peter-Katalinic J. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharm Biomed Anal 2007;44:388-395. (Pubitemid 46887640)
41. Edwards CK, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Cosenza ME, Feige U, Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003;55:1315-1336. (Pubitemid 37464564)
42. Arduini RM, Li ZF, Rapoza A, Gronke R, Hess DM, Wen DY, Miatkowski K, Coots C, Kaffashan A, Viseux N, Delaney J, Domon B, Young CN, Boynton R, Chen LL, Chen LQ, Betzenhauser M, Miller S, Gill A, Pepinsky RB, Hochman PS, Baker DP. Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif 2004;34:229-242. (Pubitemid 38390571)
43. Baker DE. Pegylated interferons. Rev Gastroenterol Disord 2001;1:87-99.
44. Eliason JF. Pegylated cytokines: Potential application in immunotherapy of cancer. BioDrugs 2001;15:705-711. (Pubitemid 33139651)
45. Kandel ER, Schwartz JH, Jessell TM. Principles of Neural Science. New York: McGraw-Hill; 2000.
46. Weller RO, Kida S, Zhang ET. Pathways of fluid drainage from the brain - Morphological aspects and immunological significance in rat and man. Brain Pathol 1992;2:277-284.
47. Johnston M. The importance of lymphatics in cerebrospinal fluid transport. Lymphat Res Biol 2003;1:41-45.
48. Abbott NJ. Evidence for bulk flow of brain interstitial fluid: Significance for physiology and pathology. Neurochem Int 2004;45:545-552.
49. Greenwald RB, Yang K, Zhao H, Conover CD, Lee S, Filpula D. Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination. Bioconjug Chem 2003;14:395-403. (Pubitemid 36348663)
50. Scarisbrick IA, Towner MD, Isackson PJ. Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 1997;17:8156-8168.
51. Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Muller F, Senn H. Structural and biophysical characterization of the 40 kDa PEG-interferon- alpha(2a) and its individual positional isomers. Bioconjug Chem 2005;16:504-517. (Pubitemid 40696041)